Skip to content
Dosage GuideResearch Reference

MOTS-c Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for MOTS-c. All information is for educational purposes only.

Quick Answer

Due to limited human research, precise MOTS-c dosing remains experimental. Current research community practice uses 5-25 mg per week, administered via subcutaneous injection, divided into 2-3 doses. Dosing is largely extrapolated from animal studies, scaled for human equivalent doses. No human clinical dose-ranging trials have been completed.

→ MOTS-c Benefits→ MOTS-c Side Effects→ Full MOTS-c Profile
Table of Contents

Standard Dosage Range

Research dosing range: 5–25 mg per week (divided into 2-3 doses)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Metabolic Health & Insulin Sensitivity

5-15 mg per week2-3× weekly
Duration

4-12 weeks

Subcutaneous injection. Dosing aimed at improving glucose utilization and insulin sensitivity. Monitor blood glucose levels and HbA1c.

Weight Management & Fat Metabolism

10-20 mg per week2-3× weekly
Duration

8-12 weeks

Subcutaneous injection. May be combined with diet and exercise for enhanced fat loss. Monitor body composition.

Exercise Mimetic & Performance Enhancement

15-25 mg per week2-3× weekly
Duration

4-8 weeks

Subcutaneous injection. Administered to potentially enhance endurance and exercise capacity. Use in conjunction with a structured training program.

Anti-Aging & Longevity Support

5-10 mg per week2× weekly
Duration

12+ weeks

Subcutaneous injection. Long-term dosing strategy focused on supporting metabolic health and counteracting age-related decline. Requires careful monitoring of health markers.

Timing & Frequency

Injections are typically administered in the morning or pre-workout, given the peptide’s potential to enhance energy and metabolism. There is no strong consensus on ideal timing given the limited human data.

Cycle Guidance

Due to the lack of long-term human safety data, cycling is a conservative approach. Common research practice uses a 8-12 week cycle followed by a 4-8 week break. MOTS-c does not directly suppress endogenous systems, so cycling rationale is primarily precautionary given limited long-term human safety data.

Reconstitution Reference

Quick reference for reconstituting MOTS-c. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 5 mg or 10 mg per vial
BAC Water Volume2.5 mL bacteriostatic water for 2 mg/mL or 4 mg/mL concentration, respectively (for a 5mg vial). 5mL for a 10mg vial to achieve 2mg/ml
Concentration & DrawAt 2 mg/mL: 1 mg = 0.05 mL (5 units on a 100-unit insulin syringe). At 4mg/ml: 1mg = 0.025ml (2.5 units on 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 30 days refrigerated. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard MOTS-c dosage for improving insulin sensitivity?
Current research community practice uses 5-15 mg per week, divided into 2-3 subcutaneous injections. Monitor blood glucose and HbA1c levels.
How often should I inject MOTS-c?
The typical protocol is 2-3 times per week. Some individuals opt for every other day injections to maintain stable blood levels.
How long does it take to see results with MOTS-c?
Subjective effects may be noticeable within the first few weeks. Objective improvements in blood glucose, body composition, or exercise capacity may take 4-12 weeks to become apparent.
Can I take MOTS-c orally?
MOTS-c is generally administered via subcutaneous injection due to concerns about oral bioavailability. Oral formulations are under investigation, but injectable forms are currently the standard for research purposes.

Last updated: 2026-02-19